Xencor (XNCR) Cash & Equivalents (2013 - 2026)
Xencor (XNCR) posted quarterly Cash & Equivalents of $14.2 million for Q1 2026, down 64.28% year-over-year from $39.7 million in Q1 2025, and down 73.79% quarter-over-quarter from $54.1 million in Q4 2025.
Analysis
Xencor (XNCR) Cash & Equivalents (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Cash & Equivalents for 14 consecutive years, with $14.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents fell 64.28% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $14.2 million (down 64.28% YoY), while the FY2025 annual figure was $54.1 million, up 32.29% from the prior year.
- Cash & Equivalents slipped to $14.2 million in Q1 2026 per XNCR's latest filing, from $54.1 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $78.3 million in Q1 2022 and bottomed at $14.2 million in Q1 2026.
- Historically, Cash & Equivalents has averaged $44.7 million across 5 years, with a median of $44.4 million in 2025.
- Annual changes were most pronounced in 2025 — Cash & Equivalents surged 44.44% — and 2026, when it plunged 64.28%.
- Xencor's Cash & Equivalents stood at $53.9 million in 2022, then retreated by 0.28% to $53.8 million in 2023, then declined by 24.01% to $40.9 million in 2024, then jumped by 32.29% to $54.1 million in 2025, then slumped by 73.79% to $14.2 million in 2026.
- Business Quant data shows XNCR's Cash & Equivalents at $14.2 million in Q1 2026, $54.1 million in Q4 2025, and $28.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.72 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 815.44 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 811.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 44.66 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.66 Mn |
| Mar 31, 2026 | 14.17 Mn |
| Dec 31, 2025 | 54.07 Mn |
| Sep 30, 2025 | 28.29 Mn |
| Jun 30, 2025 | 44.44 Mn |
| Mar 31, 2025 | 39.68 Mn |
| Dec 31, 2024 | 40.88 Mn |
| Sep 30, 2024 | 29.03 Mn |
| Jun 30, 2024 | 30.77 Mn |
| Mar 31, 2024 | 31.03 Mn |
| Dec 31, 2023 | 53.79 Mn |
| Sep 30, 2023 | 52.73 Mn |
| Jun 30, 2023 | 34.71 Mn |
| Mar 31, 2023 | 72.39 Mn |
| Dec 31, 2022 | 53.94 Mn |
| Sep 30, 2022 | 52.65 Mn |
| Jun 30, 2022 | 49.41 Mn |
| Mar 31, 2022 | 78.27 Mn |
| Dec 31, 2021 | 143.48 Mn |
| Sep 30, 2021 | 41.20 Mn |